Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim + Ganciclovir for AIDS-Related CMV Retinitis
NCT00002070Phase 3Completed
- Sponsor
- Merck & Co.
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sargramostim in cytomegalovirus retinitis and acquired immunodeficiency syndrome (AIDS) (2 arms), sponsored by Merck & Co. Primary endpoint: Tolerance to Ganciclovir. Status: completed.
02
Drugs
sargramostim
03
Conditions
cytomegalovirus retinitisacquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on NCT00002070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002070.